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Abstract 
Background: The German Diabetes Study (GDS) is a prospective longitudinal cohort study describing the impact of 
subphenotypes on the course of the disease. GDS aims at identifying prognostic factors and mechanisms underlying 
the development of related comorbidities.
Study design and methods: The study comprises intensive phenotyping within 12 months after clinical diagnosis, 
at 5‑year intervals for 20 years and annual telephone interviews in between. Dynamic tests, including glucagon, mixed 
meal, intravenous glucose tolerance and hyperinsulinemic clamp tests, serve to assess beta‑cell function and tissue‑
specific insulin sensitivity. Magnetic resonance imaging and multinuclei spectroscopy allow quantifying whole‑body 
fat distribution, tissue‑specific lipid deposition and energy metabolism. Comprehensive analyses of microvascular 
(nerve, eye, kidney) and macrovascular (endothelial, cardiorespiratory) morphology and function enable identification 
and monitoring of comorbidities. The GDS biobank stores specimens from blood, stool, skeletal muscle, subcutane‑
ous adipose tissue and skin for future analyses including multiomics, expression profiles and histology. Repeated 
questionnaires on socioeconomic conditions, patient‑reported outcomes as quality of life, health‑related behavior as 
physical activity and nutritional habits are a specific asset of GDS. This study will recruit 3000 patients and a group of 
humans without familiy history of diabetes. 237 type 1 and 456 type 2 diabetes patients have been already included.
Keywords: Insulin resistance, Magnetic resonance spectroscopy, Beta cell function, Metabolic phenotyping, Diabetes 
comorbidities
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Background
Why was the cohort set up?
Diabetes mellitus (DM), particularly type 2 DM, is a 
global health issue affecting about 387 million people [1]. 
Also type 1 DM, characterized by insulin deficiency due 
to autoimmune-mediated beta-cell destruction, is rising 
[2]. All DM types tightly associate with microvascular 
(retinopathy, nephropathy, neuropathy) and macrovas-
cular comorbidities (ischemic heart disease, peripheral 
vascular disease, cerebrovascular disease) and several 
malignancies. The resulting organ dysfunctions affect 
at least one-third of individuals with DM accounting 
for approximately 8  % of global all-cause mortality in 
humans aged between 20 and 79 years [3].
Subphenotypes of DM
Type 2 DM is characterized by a long “prediabetic” state 
with impaired insulin sensitivity, which promotes hyper-
insulinemia. With failing insulin secretion, glycemia 
increases until diagnostic thresholds for overt diabe-
tes are exceeded [4]. There is evidence for the existence 
of subphenotypes even in the prediabetic state, possibly 
resulting from differences in the pathogenesis, and also 
with regard to the course of disease and related compli-
cations. In most forms of DM, beta cell dysfunction is 
a major driving force for disease development and pro-
gression [5]. Despite extensive research on potential 
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underlying mechanisms, such as glucose- or lipid-medi-
ated toxicity [6, 7], mitochondrial dysfunction [8] or 
inflammation [9] the processes involved in beta cell fail-
ure are not fully understood [10]. Defects in pancreatic 
beta-cell function are often preceded by insulin resist-
ance [11–13] which is not only a feature of type 2 DM, 
but is also found in patients with type 1 DM [14, 15]. 
Moreover, obesity associates with increased incidence 
of type 1 DM [16, 17], which has led to the term ‘double 
diabetes’. The mechanisms linking type 1 DM and insulin 
resistance, and thereby type 2 DM, are yet unknown.
Gene variants identified by genome-wide association 
studies seem to affect DM susceptibility predominantly 
through beta-cell dysfunction but also with insulin resist-
ance [18]. The risk alleles are common in the population, 
but their effect size is small and not suitable for general 
genetic screening [19]. Identification of genetic determi-
nants for insulin resistance relied on its surrogate mark-
ers such as fasting insulin [20, 21]. If such genetic variants 
are studied in comprehensively phenotyped cohorts [22], 
novel therapy targets might be identified [23]. The dis-
tribution of subphenotypes, the predictive value for the 
development of comorbidities and the effectiveness of 
stratified or personalized treatment strategies are yet 
unclear.
Complications and diagnosis of early manifestations
In individuals at low risk of cardiovascular diseases, i.e. 
younger non-smoking normotensive women, the relative 
cardiovascular risk is multiplied by the occurrence of type 
2 DM [24]. Individuals with newly diagnosed type 2 DM 
already present comorbidities presumably due to longer-
term undetected hyperglycemia [25], while some patients 
with type 1 DM show a rapid progress of diabetes-asso-
ciated diseases [26] despite good metabolic control [27]. 
Regarding macrovascular diseases, the prognostic impor-
tance of the metabolic syndrome compared to the sum of 
its individual components has been challenged [28]. Even 
the obvious link between hyperglycemia and comorbidi-
ties appears complex [29]. The predictive value of sub-
phenotypes for the development of comorbidities and the 
effectiveness of individualized treatment strategies is far 
from being understood. GDS focusses on the presum-
ably formative early period after diagnosis of the disease 
and the thorough prospective assessment of (pre) clinical 
manifestations of comorbidities over 10 years.
Individualized intervention strategies
There is evidence for sustained protection by intensive 
glycemic control early after onset of DM, with reduction 
of mortality and micro- and macrovascular comorbidi-
ties decades thereafter, referred to as legacy effect [24, 
29]. Current glucose-lowering drugs have modest efficacy 
on diabetes endpoints, so novel therapy strategies need 
to prove additional positive effects on the development of 
comorbidities.
Nutritional behavior is an important lifestyle factor 
influencing the risk of developing type 2 DM [30] and 
to some extent of type 1 DM [31, 32]. Dietary interven-
tion in type 2 DM can improve insulin sensitivity and 
beta-cell function [33]. Accordingly, excess availability of 
certain metabolites such as free fatty acids and branched-
chain amino acids induces whole-body insulin resistance 
[34–36]. Together with gene variants related to response 
to lifestyle intervention [37], metabolome profiling will 
have impact for the development of treatment and pre-
vention strategies. The GDS has the potential to imply 
targeted interventions in selected subgroups covering a 
broad range of potential mechanisms as well as diabetic 
comorbidities.
Classical and novel risk factors
Despite the vast amount of data on classical risk fac-
tors, the impact of novel biomarkers, e.g. identified by 
multiomics technologies or innovative imaging tools is 
incompletely understood [38, 39]. The majority of epi-
demiological studies have estimated insulin resistance 
from surrogate parameters, yielding incorrect results in 
patients with impaired beta-cell function [40–42]. There-
fore, we aimed at standardizing methods for comprehen-
sive metabolic phenotyping and implementation of novel 
tools in the initial period between 2005 and 2009. The 
updated validated study program started in 2009 with a 
focus on cellular mechanisms of insulin resistance. High 
lipid availability and ectopic lipid deposition in skeletal 
muscle and the liver play a central role in the develop-
ment of insulin resistance [43] but the cellular mecha-
nisms remain unknown [44, 45]. Regulators of subcellular 
lipid partitioning and mitochondrial oxidation strongly 
determine insulin sensitivity but are only partially under-
stood [46].
Both DM and its comorbidities have in common that 
inflammation-related processes are involved in their 
development [47–49]. The current knowledge on the 
relevance of biomarkers of subclinical inflammation is 
mainly restricted to studies on hard cardiovascular end-
points in patients with type 2 DM [47–50]. Prospective 
data are limited on associations of inflammation and 
quantitative phenotypes in earlier stages of cardiovascu-
lar disease and all stages of microvascular comorbidities 
or cognitive decline and are mainly derived from cohorts 
of patients with type 1 DM. We hypothesize that circu-
lating biomarkers of subclinical inflammation predict the 
deterioration of insulin sensitivity and beta-cell function 
and the progression of micro- and macrovascular comor-
bidities in patients with newly diagnosed DM.
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For the identification of novel predictors, most previ-
ous studies included patients with longer DM duration 
[51–53]. Therefore, we acquire circulating biomarkers of 
subclinical inflammation, non-invasive data on energy 
and lipid metabolism in liver and skeletal muscle and 
store biopsy samples of skeletal muscle and subcutaneous 
adipose tissue for future analyses.
Sociodemographic and psychosocial determinants 
have been discussed as modifiable regulators of the 
course of DM. These include e.g. socioeconomic posi-
tion, health-related quality of life and mental disorders 
[54–57]. Knowledge about the changes of innovative 
patient reported measures such as patients’ preferences, 
information needs and time needed for health-related 
activities [58, 59] during the progression of the disease is 
lacking so far.
The aims for setting up the GDS were identification of 
(i) sub-phenotypes of DM with respect to insulin sensi-
tivity, insulin secretion and (ii) predictors of early diabe-
tes-related comorbidities, (iii) to develop individualized 
intervention strategies for the treatment and prevention 
of diabetes and related comorbidities (iv) to analyze the 
impact of known and novel risk factors (i.e. nutrition, 
subclinical inflammation, energy metabolism, body fat 
distribution, metabolites and other biomarkers, socioec-
onomic and psychosocial conditions) on disease progres-
sion and development of diabetes-related comorbidities, 
in recently diagnosed patients with type 1 and type 2 
DM. GDS will test the hypothesis that the course of DM 
and related comorbidities is determined by processes 
that depend on diabetes type, affecting immunological 
factors, energy homeostasis, body fat composition and 
distribution and patient reported measures.
Study design and methods
The GDS is an ongoing prospective observational study 
comprising intensive phenotyping within 12 months after 
clinical diagnosis, at 5-year intervals for at least 20 years 
and annual telephone interviews in between. The study 
is performed according to the Declaration of Helsinki, 
approved by the ethics committee of the University of 
Düsseldorf (previous reference number 2478, current ref-
erence number 4508) and was registered at Clinicaltrials.
gov (Identifier number: NCT01055093).
Who is in the cohort?
The primary inclusion criterion is diagnosis of DM 
according to current ADA recommendations [60] within 
the last 12  months in individuals aged between 18 and 
69  years. These include maturity onset diabetes of the 
young (MODY) and latent autoimmune diabetes of the 
adult (LADA), while individuals suffering from type 3 
(e.g. pancreoprive DM) or type 4 (gestational) DM are 
not included. The main inclusion criteria are provided 
in detail in Table 1. The recruitment was performed via 
advertisements in local newspapers and the institutional 
homepage and via practitioners we supplied with infor-
mation and flyers. After receiving the contact details, the 
potential participants were contacted and prescreened 
in a detailed telephone interview to check the inclusion 
and exclusion criteria. Appropriate applicants were then 
invited to the first study day including physical examina-
tion and anamnesis, thereafter participation in the more 
advanced examination was decided upon. From 2015 on 
a glucose tolerant subgroup matched for sex, BMI and 
age will be included to the data base. Participants give 
written informed consent to the study protocol.
By 01/2015 240 type 1 and 458 type 2 DM patients and 
three patients with MODY were included. GDS (in Ger-
many named Deutsche Diabetes-Studie, DDS) was initi-
ated at the German Diabetes Center (Deutsches Diabetes 
Zentrum, DDZ), Leibniz Center for Diabetes Research 
at Heinrich Heine University, Düsseldorf, Germany and 
developed into a national multicenter study with ongo-
ing inclusion of patients from different regions of Ger-
many being a core research project within the German 
Center of Diabetes Research (DZD e.V.) since 2014. The 
other partners and associates of DZD e.V. now contribut-
ing to GDS with increasing numbers include alphabeti-
cally listed the Department of Endocrinology/University 
Hospital Schleswig–Holstein; Department of Medicine 
I and Clinical Chemistry, University of Heidelberg; Fac-
ulty of Medicine/University Hospital Carl Gustav Carus, 
Dresden; Faculty of Medicine/Ludwig Maximilians Uni-
versity, Munich; German Institute of Human Nutrition 
Potsdam Rehbruecke; and Institute for Diabetes Research 
and Metabolic Diseases at Eberhard Karls University, 
Tübingen.
How often will they be followed up?
All patients undergo the full test program at baseline, 
at 5 and 10 years after diagnosis, and shall be continued 
thereafter. In between, a standardized telephone inter-
view is conducted in annual intervals. During the initial 
phase of the study, the full test program was also repeated 
after 2 years in 137 patients. The annual telephone inter-
views reach a response rate of around 83 %. The 5-year 
follow-up started in 2014 and shows a response rate of 
61  %. Another 33  % of patients are potential respond-
ers as they are still within the allowed time frame, while 
6  % are lost to follow-up. Of those lost to follow up, 
48 % refrained from further participation, 33 % were not 
accessible, 11 % died, 4 % refused for lack of time and 4 % 
showed non-compliance to the protocol.
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What is measured?
In addition to demographic data (Table  2), baseline 
and follow up assessments include clinical and meta-
bolic variables at baseline and follow up, summarized 
in Table 3. To address the issue of beta-cell dysfunction, 
the phenotyping includes assessment of beta-cell func-
tion using the glucagon stimulation test and mixed meal 
tolerance test (MMTT) [61]. In addition, the Botnia 
clamp consists of an intravenous glucose tolerance test 
(IVGTT [62]) for further testing of beta-cell function 
followed by a hyperinsulinemic-euglycemic clamp test 
providing precise dynamic measures of insulin secre-
tion and sensitivity [63, 64]. Hepatic insulin sensitiv-
ity is measured by co-infusion of [6,6-2H2]glucose [65]. 
Cycling ergospirometry is performed to measure cardi-
orespiratory performance [37], indirect calorimetry to 
assess energy expenditure and substrate oxidation dur-
ing fasting and hyperinsulinemia [66]. The experimental 
protocols are described in the Additional file 1: Annex-
ure 1.
RNA and DNA samples are purified from whole-
blood and peripheral blood mononuclear cells (PBMCs), 
serum and plasma samples (citrate, EDTA) are stored at 
−80 °C for analysis of biomarkers [67, 68]. Neurological 
and cutaneous microvascular assessments include nerve 
conduction studies, quantitative sensory testing, neu-
ropathic symptoms and deficits, heart rate variability, 
baroreflex sensitivity, pupillography, sudomotor function, 
sexual function, intraepidermal nerve fiber density, cor-
neal confocal microscopy, laser Doppler flowmetry, skin 
autofluorescence [69–72], opthalmological examinations 
include funduscopy, corneal esthesiometry [73] and opti-
cal coherence tomography (OCT) [74].
In mid-2012 acquisition of skeletal muscle and subcu-
taneous abdominal adipose tissue samples and magnetic 
resonance imaging and spectroscopy (MRI/S) exami-
nations were implemented. Absolute quantification of 
phosphorus metabolites in the liver and recovery of 
phosphocreatine after depletion through exercise in skel-
etal muscle have been applied for the estimation of tissue 
specific energy metabolism [75]. Assessment of whole 
body fat distribution and ectopic lipid storage is assessed 
from proton spectroscopy and MRI.
Patient-reported outcomes are assessed via question-
naires at baseline and follow-up investigations and dur-
ing annual telephone interviews (Table  3), reflecting 
quantitative analysis of lifestyle, course of the disease, 
compliance and socio-economic factors associated with 
the disease, and dietary habits. Participation preferences, 
information needs and time for health related activities 
are assessed by the Control Preferences Scale, the Auton-
omy Preference Index and questionnaires developed and 
validated in the DDZ, and diabetes self-management 
instruments which are well established in cohort stud-
ies [76–80]. Quality of life and depression are assessed by 
common questionnaires (Table 4).
Discussion
What has it found? key findings and publications
Baseline characteristics
The basal characteristics of the cohort recruited between 
01/2009 and 1/2015 are summarized in Table  2. In our 
Table 1 Key exclusion criteria
a  American Diabetes Association [60]
Key inclusion criteria Key exclusion criteria Exclusion criteria for specific examinations
Diagnosis of type 1 DM and type 2 DM 
including maturity onset diabetes of 
the young (MODY) and latent autoim‑
mune diabetes of the adult (LADA) 
based on current ADA recommenda‑
tionsa
Onset of DM within the last 12 months
Diagnosis of type 1 DM based on dia‑
betes manifestation with ketoacidosis 
or immediate insulin requirement 
along with the presence of at least 
one islet cell directed autoantibody or 
C‑peptide levels below detection limita
Age of 18–69 years
Secondary DM according to ADA criteria 
(Type 3 B‑H, e.g. pancreoprive DM)
Type 4 (gestational) DM, pregnancy
Poor glycemic control (HbA1c > 9.0 %)
Hyperlipidemia (triglycerides and low‑den‑
sity lipoproteins ≥double upper reference 
limit)
Heart, renal, liver failure (NYHA ≥II, serum 
creatinine ≥1.6 mg/dl, Aspartate‑Ami‑
notransferase/Alanine‑Aminotransferase/
Gamma‑Glutamyltransferase
Peripheral artery occlusive disease IV
Venous thromboembolic events
Anemia, blood donation or participation in a 
clinical study within the past 3 months
Acute infection, leukocytosis, immunosup‑
pressive therapy, autoimmune diseases, 
infection with human immunodeficiency 
virus, other severe diseases (e.g. active 
cancer disease)
Psychiatric disorders, limited cooperation 
ability
Neurologic examination: corneal disorders, and neuropathy 
from causes other than diabetes
Spiroergometry: electrocardiogram abnormalities (alterations 
of the ST segment, higher‑grade arrhythmia), unstable 
angina pectoris, uncontrolled hypertonia
Magnetic resonance spectroscopy/imaging: metallic implants 
(cardiac pacemaker or defibrillator, cochlear implants, 
implanted catheters, clips, prosthetic valves), metallic 
fragments (metal removed from eye, ever worked as metal 
worker), larger tattoos, waist circumference > 135 cm, 
claustrophobia
Tissue biopsies: effective anticoagulation therapy, platelet 
aggregation inhibitors >100 mg acetylsalicylate
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cohort, the percentage of patients diagnosed with type 2 
DM at an age of less than 45  years, commonly referred 
to as “early manifestation of type 2 DM” is doubled com-
pared to US registry data (Table  2) [81–83]. This might 
Table 2 Baseline characteristics of  type 1 and  type 2 dia-
betes patients
Type 1 DM Type 2 DM
Age (%) (%)
 15–19 5.4 0.2
 20–24 15.0 1.1
 25–29 16.7 1.7
 30–34 18.0 3.1
 35–39 10.0 4.6
 40–44 9.6 8.5
 45–49 8.7 15.3
 50–54 10.4 16.2
 55–59 2.5 17.2
 60–64 3.0 18.8
 65–69 0.8 13.1
 70–74 0 0.2
Sex
 Male 62.5 67.0
 Female 37.5 33.0
Marital status
 Single 55.0 21.8
 Co‑habiting/married 40.8 61.6
 Separated/divorced 3.7 12.4
 Widowed 0.4 4.1
Higher education
 Up to class 8 9.6 27.1
 Junior high school 20.0 22.5
 Up to class 10 0.0 5.0
 Advanced technical college 13.3 12.2
 Secondary school examination 55.0 30.6
 No education 0.4 0.7
 Other types of education 1.2 1.7
 No response* 0.4 0.2
Employment
 Laborer 9.2 16.2
 Employee 54.6 61.3
 Official 5.4 5.0
 Business man 7.2 10.0
 Farmer 0 0.2
 Self‑employed worker 2.1 3.5
 Non‑employed 0.8 0
 Other professions 5.4 1.5
 No response/advanced educationa 1.2 0.2
Medical insurance
 Private 15.8 12.4
 Government/public 77.9 81.9
 Other insurance 5.8 4.6
 No insurance 0 0
 No response 0.5 1.1
Regular medical checks
 Yes 35.8 56.1
Demographic characteristics of the type 1 and type 2 diabetes mellitus (DM) 
patients included until 01/2015 at baseline in  % of whole study group. DSPN: 
diabetic sensorimotor polyneuropathy, CAN: cardiovascular autonomic 
neuropathy. DSPN and CAN were defined as previously reported (68, 98)
a No response refers to the number of participants, who prefer not to answer to 
a specific question during the interview
Table 2 continued
Type 1 DM Type 2 DM
 No 63.7 42.8
 No responsea 0.4 0.9
Family history of diabetes
 Mother 16.1 32.7
 Father 17.3 26.3
 Children 0.8 1.7
 Brothers and sisters 7.6 18.4
 Grandparents 37.3 35.2
 Uncles and aunts 15.8 20.0
Other diseases/risk factors/comorbidities
 Hypertension 18.5 63.3
 History of myocardial infarction 0.4 2.8
 Retinopathy 0.8 1.3
 History of or current smoking 73.3 88.9
 Subclinical DSPN 9.8 6.9
 Confirmed asymptomatic DSPN 0.4 2.6
 Confirmed symptomatic DSPN 2.2 4.0
 Possible DSPN 7.2 23.2
 Probable DSPN 0.5 5.3
 Subclinical/borderline CAN 0.9 2.1
 Definite CAN 1.4 2.4
Medication
Glucose lowering therapy
 Insulin, short acting 87.9 5.9
 Insulin, long acting 54.2 4.8
 Metformin 14.6 56.1
 Sulfonylurea 1.3 3.5
 Dipeptidyl‑peptidase‑4 inhibitors 1.3 6.6
 GLP‑1‑Agonists 0.4 2.0
Other therapies
 Acetylsalicylic acid 1.7 11.1
 Statins 2.5 17.5
 Fibrates 0.0 0.7
Any antihypertensive therapy
 Blockers of the renin‑angiotensin system 2.1 15.9
 Beta blockers 2.9 25.3
 Calcium channel blockers 0.8 13.8
 Diuretics 0.4 8.3
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result from the higher willingness of younger persons 
to participate in time-consuming examinations. Such 
higher motivation could also reflect their higher educa-
tional levels compared to other cohorts of newly diag-
nosed type 2 DM. Accordingly, mean age at diagnosis 
was comparable to cohort studies that excluded elderly 
patients [84, 85] (Table 2b). The percentage of male type 
2 DM participants is higher compared to other cohorts, 
which might result from more frequent manifestation in 
males <65 years [86–88]. Our observational study is not 
designed as a population-based study and therefore does 
not claim to represent the German diabetes population, 
but intends to reveal predictors of later outcome in spe-
cific subgroups and to unravel underlying mechanisms. 
We now post this statement and compare our baseline 
description of the first included patients to one report 
of Hartwig et  al., who reviewed four large representa-
tive regional cohorts of incidental type 2 diabetes and 
the data from the national German Health Interview and 
Examination Survey for Adults (DEGS), which combines 
a nationally representative health survey and a longitudi-
nal follow-up of participants from the previous German 
National Health Interview and Examination Survey in 
1997–1999 [89]. The participants of our cohort include 
younger patients and more males than represented in this 
reference study, while the body mass index is compara-
ble. The mean body mass index at baseline is also compa-
rable to other European cohorts [84, 86–88].
The mean body mass index at baseline is comparable to 
other European cohorts [84, 86–88]. A high proportion 
of type 2 DM patients demonstrated evidence of modifi-
able cardiovascular risk factors at diagnosis. Participants 
with newly diagnosed type 1 DM were leaner and younger 
compared to type 2 participants (Table  2a). In line with 
type 1 DM intervention studies, a remarkable number 
still had residual beta-cell function (Fig. 1a) [90–93]. We 
reported the possible effects of low-grad inflammation 
and dietary habits on maintenance of residual beta-cell 
function in follow-up examinations 2 years after diagno-
sis [94]. Future follow-up examinations will unravel the 
role of other factors, that are currently under discussion, 
body fat distribution i.e. liver fat content. On the other 
hand, we found that a substantial number of type 1 DM 
patients showed decreased insulin sensitivity, which is 
in line with previous reports [14, 95] and might relate 
to poor glycemic control [96] or other mechanisms also 
attributable to type 2 DM [97] (Fig.  1b). In addition to 
insulin treatment 15 % of type 1 DM patients were treated 
with metformin, a few had oral glucose lowering agents 
and 8  % were not treated with insulin yet (Table  2a). 
Table 3 Clinical parameters at  baseline in  (a) type 1 and   
(b) 2 diabetes patients
Number (N) of type 1 (DM) participants or samples, M mean, SD standard 
deviation, Med median, LQ lower quartile, UQ upper quartile, HDL high-density 
lipoprotein, LDL low-density lipoprotein, ASAT Aspartate-Aminotransferase, 
ALAT Alanine-Aminotransferase, GGT Gamma-Glutamyltransferase, hsCRP high 
sensitive C-reactive protein, SBP systolic blood pressure, DBP diastolic blood 
pressure. VO2max maximal oxygen uptake, FMD flow-mediated (endothelium-
dependent) vasodilatation, NMD nitrogen-mediated (endothelium independent) 
vasodilatation
N M ± SD LQ/UQ Med
Panel a
Age (years) 240 36.0 ± 11.8 26.3/45.4 34.0
Body mass index (kg/m2) 240 24.8 ± 4.1 22.0/26.6 24.0
Waist circumference (cm) 239 86.1 ± 12.6 76.2/94.0 85.0
Hemoglobin A1c (%) 237 6.5 ± 1.2 5.8/6.9 6.3
Glucose (mg/dl) 232 133.4 ± 48.0 106.0/150.5 121.0
Total cholesterol (mg/dl) 238 184.9 ± 38.6 160.5/207.5 180.5
HDL cholesterol (mg/dl) 236 60.5 ± 17.3 48.5/70.5 59
LDL cholesterol (mg/dl) 236 108.9 ± 33.5 87.0/126.5 105.0
Triglycerides (mg/dl) 238 89.6 ± 58.2 56.0/102.0 74.0
ASAT (U/l) 238 22.4 ± 8.5 17.0/25.0 20.2
ALAT (U/l) 238 25.2 ± 18.5 15.9/28.0 20.9
GGT (U/l) 238 22.1 ± 21.7 11.1/26.0 16.0
hsCRP (mg/dl) 237 0.2 ± 0.3 0.1/0.2 0.1
C‑peptide (ng/ml) 236 1.2 ± 0.9± 0.5/1.4/ 1.0
SBP (mmHg) 237 129.5 ± 14.9 120.5/138.0 129.0
DBP (mmHg) 237 78.0 ± 9.8 71.0/84.0 77.0
VO2max (ml min.
−1 kg−1) 203 27.0 ± 7.8 22.1/31.3 25.7
FMD (%) 201 6.8 ± 6.6 2.2/10.6 5.6
NMD (%) 196 16.4 ± 9.5 9.3/22.1 15.8
Panel b
Age (years) 458 53.5 ± 10.4 47.1/62.4 54.8
Body mass index (kg/m2) 456 31.7 ± 6.0 27.1/35.4 31.1
Waist circumference (cm) 455 105.9 ± 14.7 95.0/115.5 105.5
Hemoglobin A1c (%) 452 6.4 ± 0.8 5.8/6.8 6.2
Fasting glucose (mg/dl) 438 125.0 ± 28.6 107.0/137.0 122.0
Total cholesterol (mg/dl) 451 206.2 ± 42.0 180.0/234.0 203.0
HDL cholesterol (mg/dl) 448 46.4 ± 12.8 37.0/53.0 45.0
LDL cholesterol (mg/dl) 448 130.5 ± 36.1 105.2/153.5 129.0
Triglycerides (mg/dl) 451 176.0 ± 165.2 98.0/203.8 137.0
ASAT (U/l) 451 25.4 ± 11.0 19.0/29.0 23.0
ALAT (U/l) 451 34.5 ± 19.5 21.9/41.8 29.0
GGT (U/l) 451 43.0 ± 51.0 21.4/48.0 31.6
hsCRP (mg/dl) 446 0.4 ± 0.7 0.1/0.5 0.3
C‑peptide (ng/ml) 445 3.3 ± 1.6 2.2/4.2 3.0
SBP (mmHg) 447 141.6 ± 17.1 129.5/152.0 141.5
DBP (mmHg) 447 85.1 ± 10.5 78.0/91.5 84.5
VO2max (ml min.
−1 kg−1) 317 19.1 ± 4.9 15.6/21.8 18.7
FMD (%) 332 5.6 ± 5.3 1.9/8.25 4.5
NMD (%) 338 12.2 ± 7.3 6.6/16.2 11.5
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These data show that type 1 DM patients may have oral 
glucose lowering at diagnosis of the disease before estab-
lishing the correct diagnosis. Cardiorespiratory fitness as 
assessed from oxygen uptake at maximal workload during 
spiroergometry (VO2max) is often impaired in patients 
with type 2 DM [98]. Accordingly, VO2max was lower in 
patients with type 2 DM compared to patients with type 
1 DM and corresponded to values reported previously 
(Table  3a, b). Reduced VO2max might also be due to 
reduced mitochondrial oxidative capacity, sedentary life 
style and possibly due to higher hepatocellular lipids and 
might predispose to the development of insulin resistance 
[99, 100]. Inverse correlation of VO2max with IL-6 and 
hsCRP in healthy men [101] and with hsCRP, white blood 
cell count and fibrinogen in men with T2D [102] suggest 
that lower VO2max might predispose to the development 
of cardiovascular disease in diabetes [103].
Endothelial-mediated (flow-mediated) and endothe-
lial-independent (nitrogen-induced) vasodilatation of 
patients with type 2 DM (Table 3b) were in the range of 
previous studies in patients with type 2 DM without pre-
vious cardiovascular events [104] and higher compared 
to baseline parameters in a number of statin intervention 
studies [105] which might be due to the shorter period 
of diabetes, the lower cholesterol levels, better glycemic 
control and the inclusion of patients undergoing statin 
treatment, factors that are known to positively correlate 
with vasodilatation. Endothelial function of type 1 DM 
patients corresponded to values in healthy control of 
similar body mass and age [104].
Overall in case of type 2 DM patients, 41.9  % had 
plasma triglycerides >150 mg/dl, 23.3 % had plasma low-
density lipoproteins <160 > 150 mg/dl, 73.6 % had blood 
pressure >130/85 mmHg and 62.5 % were overweight or 
obese (Fig. 1c–f). At baseline, 18 % of type 2 DM patients 
were receiving a statin, 9 % were receiving a fibrate, 11 % 
were being treated with an acetylsalicylic acid agent, and 
55 % were receiving any drug for blood pressure reduc-
tion (Table  2). The percentage of statin use is low, par-
ticularly in type 2 diabetes patients and cardiovascular 
risk factors are not perfectly controlled at the onset of 
diabetes (Fig. 1; Table 2).
Summary of the results obtained so far
By beginning of 2015, GDS yielded 13 original articles 
published in peer-reviewed journals [35, 64, 66, 69–71, 
75, 106–111].
Standardization of experimental protocols
  • The measures of insulin sensitivity derived from the 
Botnia clamp were validated against the standard 
hyperinsulinemic-euglycemic clamps in patients with 
type 2 DM [64].
  • Post-calorimetric individual calibration procedures 
have been developed to increase the accuracy and 
comparability of indirect calorimetry assessed in dif-
ferent centers [66].
  • Blood glucose measuring instruments were validated 
against gold-standard method and the method with 
the highest accuracy was selected [107].
Establishment of novel methods for metabolic imaging
  • At DDZ, noninvasive phosphorous (31P) MRS of liver 
was established and optimized with short examina-
tion time on a 3-T clinical magnet [75]. With this 
method, GDS started to employ quantifying absolute 
concentrations of hepatic adenosine triphosphate 
(ATP) and inorganic phosphate (Pi) as measures of 
liver energy metabolism [112].
  • Rapid methods for the quantification of hepatic and 
pancreatic fat were developed applicable to larger 
cohorts, showing that no relationship exists between 
pancreatic adipose tissue infiltration and beta cell 
function, regardless of glucose tolerance status [109, 
110].
Development of comorbidities
  • Immune cell phenotyping showed distinct occur-
rence of certain white blood cell subtypes and associ-
ations with insulin sensitivity, glycemia and lipidemia 
in patients with type 1 and type 2 DM [106].
  • The sensitivity of an indicator test for sudomotor dys-
function on the foot (Neuropad) for detecting small 
fiber dysfunction was relatively high in recently diag-
nosed type 1 DM (80 %) and somewhat lower in type 
2 DM (68 %) (64). Thus, early sudomotor dysfunction 
may be demonstrated by screening in recent-onset 
diabetes.
  • Using novel methods to quantify small nerve fiber 
density (NFD) including corneal confocal microscopy 
and skin biopsy early nerve pathology was detected in 
up to 20 % of subgroups with type 2 DM participat-
ing in the GDS [69–71]. However, the vast majority 
of patients with abnormal corneal NFD showed con-
comitantly normal intraepidermal NFD and vice versa. 
Thus, both techniques detect early nerve fiber loss in 
recently diagnosed type 2 DM, but largely in different 
patients, suggesting a patchy manifestation pattern of 
small fiber neuropathy. Recently diagnosed type 2 DM 
patients also demonstrate a marked reduction of cuta-
neous Langerhans cell density, which relates to insulin 
resistance in women [69]. Prospective data will estab-
lish whether the initial Langerhans cell decline could 
promote a cutaneous immunogenic imbalance toward 
inflammation predisposing to polyneuropathy and 
foot ulcers. Moreover, dermal expression of mitochon-
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Table 4 Questionnaires at baseline and follow-up
Questions and questionnaires at baseline, 5-year follow-up, 10-year follow-up, and annual telephone interview. Y stands for ‘yes’ (question asked) and N stands for ‘no’ 
(question not asked)
Short form 36 health survey questionnaire (SF36), World Health Organization 5 questions health survey (WHO5), World Health Organisation quality of life assessment 
(WHOQOL-Bref ), symptom checklist 14 (SCL-14), patient health questionnaire (PHQ), problem areas in diabetes (PAID), Allgemeine Depressionsskala (ADS-L), Control 
Preferences Scale (CPS), Autonomy Preference Index (API)
Baseline 5-year follow-up 10-year follow-up Telephone interview
Demographics
 Age Y N N N
 Sex Y N N N
 Marital status Y Y Y Y
 Retardation/physical disabilities Y Y Y Y
Diabetes
 Time of diagnosis Y N N N
 Symptoms at time of diagnosis Y N N N
 Diabetes treatment regime Y Y Y Y
 Diet plan and advice Y Y Y Y
 Diabetes education for the patients Y Y Y Y
 Ophthalmological complications Y Y Y Y
 Kidney complications Y Y Y Y
 Cardiovascular complications Y Y Y Y
 Neurological complications Y Y Y Y
 Cerebrovascular complications Y Y Y Y
 Radiation exposure in last 10 years Y Y Y Y
 Family history of diabetes and other diseases Y Y Y Y
Socio‑economic status
 Household composition Y Y Y Y
 Education Y Y Y Y
 Health insurance Y Y Y Y
 Employment Y Y Y Y
 Net household income Y Y Y Y
Personal health behavior, life style
 Smoking Y Y Y Y
 Alcohol Y Y Y Y
 Physical activity Y Y Y Y
 Food frequency questionnaire Y Y Y Y
 Regular medical checks Y Y Y Y
 Personal health history
 Other diseases Y Y Y Y
 Food supplement intake Y Y Y Y
 Other medication Y Y Y Y
 Self reported weight and weight change Y Y Y Y
 Mental health Y Y Y Y
 Reproductive history Y Y Y Y
Health‑related quality of life
 WHO‑5, SF‑36 Y Y Y Y
 WHOQUOL‑Bref, SCL‑14 Y Y Y N
Depression
 PHQ, PAID, ADS‑L Y Y Y Y
Information needs, patient time
 CPS, API
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drial superoxide dismutase (SOD2) expression in the 
lower limbs was augmented by ≈60 % and correlated 
with increasing diabetes duration, cardiac sympathetic 
predominance, and diminished vagal activity, while 
subepidermal endothelial cell area was not altered. The 
SOD2 overexpression points to an early enhanced, 
presumably compensatory, cutaneous anti-oxidative 
defence in type 2 DM [111]. Whether cutaneous 
SOD2 levels can predict the development of diabetic 
neuropathy will be determined during the prospective 
GDS follow-up.
  • Assessing various single nucleotide polymorphisms 
(SNPs) in the transketolase gene, we observed asso-
ciations of genetic variability in transketolase enzyme 
with neuropathic symptoms and reduced thermal 
sensation in the GDS baseline cohort, suggesting a 
role of pathways metabolizing glycolytic intermedi-
ates in early diabetic neuropathy.
  • Using the diagnostic criteria for diabetic sensorimo-
tor polyneuropathy (DSPN) based on the Toronto 
Consensus (85), the prevalence of DSPN was relatively 
high, achieving 20  % in individuals with type 1 DM 
and 42  % in those with type 2 DM (Table  3). DSPN 
was subclinical in 10 % of the type 1 DM subjects and 
possible in 23 % of those with type 2 DM. The preva-
lence of confirmed DSPN was relatively low, with 3 % 
in individuals with type 1 DM and 7 % in those with 
type 2 DM, similar to the prevalence of cardiovascular 
autonomic neuropathy (CAN) at 2 % in type 1 DM and 
5 % in type 2 DM patients. The rate of DSPN strongly 
depends on the definition of DSPN and is consider-
ably lower, if both clinical and electrodiagnostic crite-
ria are combined. The prevalence of definite CAN in 
GDS participants with type 2 DM (2.4 %) is similar to 
the rate of 1.8 % observed by the Verona Newly Diag-
nosed Type 2 Diabetes Study (VNDS) [113]. Likewise, 
the prevalence of DSPN found in the present study is 
compatible with the percentages of 4–39 % depending 
on the different definition criteria for DSPN used in 
cohorts of newly diagnosed DM patients [114].
  • Biomarkers of subclinical inflammation are associ-
ated with DSPN and both motor and sensory nerve 
conduction velocity (NCV). High serum IL-6 was 
associated with the presence of DSPN and reduced 
motor NCV in type 2 DM. In addition, higher lev-
els of high-molecular weight (HMW) and total adi-
ponectin were consistently associated with DSPN 
and both reduced motor and sensory NCV in indi-
viduals with type 2 DM. In participants with type 1 
DM however, associations between high adiponectin 
and higher motor NCV were found. Thus, our data 
support the hypothesis that the pathomechanisms 
leading to DSPN may only partially overlap between 
type 1 and type 2 DM [115].
Cellular mechanisms of insulin resistance
  • In a subgroup of type 2 DM patients, we assessed 
cellular mechanisms of insulin resistance in skeletal 
muscle [35]. These data provided evidence that spe-
cific diacylglycerol species underlie activation of pro-
tein kinase C, which impairs insulin signaling.
  • In a subgroup of type 2 DM participants, we analysed 
effect of low-caloric interventions on insulin sensi-
tivity and found that energy restriction per se seems 
to be key for improving insulin action in phases of 
active weight loss in obese type 2 DM, with a poten-
tial improvement of subclinical inflammation with a 
diet free of red meat [108].
  • Higher levels of biomarkers of subclinical and vas-
cular inflammation were found associated with the 
deterioration of glycemic control and decreases in 
beta-cell function in study participants with recently 
diagnosed type 1 and type 2 DM [94].
What are the main strengths and weaknesses?
The main strength is the broad spectrum of comprehen-
sive metabolic phenotyping combining gold standard 
methods with novel techniques in humans shortly after 
diagnosis of DM at regular intervals for 20  years. The 
examinations combine highly specialized tests, such as 
non-invasive cutting-edge metabolic imaging, micro 
methods applied to tissue biobanks and blood samples, 
which have not been used in previous long-term stud-
ies. The array of morphological and functional measures 
allows for recording preclinical occurrence of comorbidi-
ties and will allow for large scale interventional studies.
Detailed test results are sent to both participants 
and their physicians, and diabetes information days 
are organized at DDZ to keep patients informed and to 
increase compliance of the participants.
One weakness is that GDS includes only people living 
in Germany and cannot represent all ethnicities (Addi-
tional file 2: Annexure 2).
Another challenge is present by potential sample size 
limitations. Since the GDS study is not a randomized trial 
with a single pre-specified hypothesis, but a very complex 
cohort study with many observed and calculated vari-
ables, all exemplarily performed sample size calculations 
were based on a logistic regression model for a binary 
response and a single binary or continuous covariate. 
Standard regression analyses in cohort studies in gen-
eral involve additional covariates for confounder adjust-
ment. Therefore, all initially calculated sample sizes can 
easily be inflated by a variance inflation factor (VIF) and 
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a factor for the expected dropout rate in the study [116]. 
As an example, considering as a response the incidence 
of peripheral diabetic neuropathy (DPN) within 10 years 
after baseline and a properly/poorly regulated HbA1c 
value (defined as ≤/> 6.5 %) as covariate, further, assum-
ing an annual incidence of DPN of approx. 2 %, a poorly 
Fig. 1 Beta‑cell function as assessed from increase of C‑peptide during the glucagon stimulation test (C‑peptide concentration at 6 min after injec‑
tion minus C‑peptide concentration at baseline) (a, n = 216 patients with type 1 DM, n = 374 patients with type 2 DM), insulin sensitivity (M value) 
as assessed from euglycemic‑hyperinsulinemic clamp tests in patients with type 1 DM or type 2 DM (b, n = 204 patients with type 1 DM, n = 351 
patients with type 2 DM), high‑density lipoprotein levels (HDL, c, n = 236 patients with type 1 DM, n = 448 patients with type 2 DM), low‑density 
lipoprotein levels (LDL, d, n = 236 patients with type 1 DM, n = 448 patients with type 2 DM), systolic blood pressure (e, n = 237 patients with type 
1 DM, n = 447 patients with type 2 DM), and diastolic blood pressure (f, n = 237 patients with type 1 DM, n = 447 patients with type 2 DM)
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regulated HbA1c in the GDS cohort of 42.5  %, and an 
odds ratio of 1.95 to be clinically relevant, a test at level 
α = 0.05 with power of 80 % to detect this odds ratio if 
480 probands are included in the cohort. when addition-
ally allowing for confounder adjustment by a VIF of 20 % 
and a dropout rate of 40 %, then at least 999 participants 
are required.
Potential selection bias includes higher social stand-
ards, the acquisition of scientific knowledge and gath-
ering more information on the disease being the most 
important motivation for the participants since the 
study protocol is time consuming and demanding and 
includes invasive examinations at low expense allow-
ance. Deep phenotyping results in detailed information 
that is provided to the practitioner. This may induce a 
change of the treatment strategy. Baseline assessment, 
yearly phone interviews and reassessments every 5 years 
might increase motivation to adhere to the therapy rec-
ommendations and thereby might refer to as a kind of 
intervention compared to other patients that were not 
included. Thus, in addition to the mentioned selection 
bias, these factors might confound the outcome meas-
ures. The participants received the results on the clinical 
examinations such as beta cell function, insulin sensitiv-
ity, cardiorespiratory fitness, liver fat content, (pre)clini-
cal onset of retinopathy or neuropathy, assessment of 
dietary habits and laboratory measures and had the 
opportunity to discuss these findings with a medical doc-
tor and a nutritionist. Assessment of preclinical mani-
festation of comorbidities may remain without distinct 
immediate clinical consequence. Incidental findings, e.g. 
abnormalities found during magnetic resonance imag-
ing are communicated to the participant and the prac-
titioner for further diagnostic steps to be taken. At the 
same time the investigator is not obligated to assess clini-
cal findings beneath the scope of the research question. 
This approach is approved by the ethical committee and 
explained to the participants prior to inclusion.
Can I get hold of the data? Where can I find out more?
A request and transfer process has been established so 
that researches may apply for data by contacting the 
study coordinators via email (GDS@ddz.uni-duessel-
dorf.de). Once approved by the steering committee, 
the requesting researcher and the principal investiga-
tor of GDS sign a contract on the terms and conditions 
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